Pharmacokinetics of imipenem/cilastatin in neutropenic patients with haematological malignancies.

Autor: Janmohamed, R. M. I., Leyland, M. J., Kelly, J., Farrell, I., Janmohamed, R M
Zdroj: Journal of Antimicrobial Chemotherapy (JAC); Mar1990, Vol. 25 Issue 3, p407-412, 6p
Abstrakt: The pharmacokinetics of imipenem/cilastatin were studied in febrile neutropenic patients with haematological malignancies. The peak plasma concentrations (36·4±4·96 mg/l), plasma half-life (60 min), volume of distribution (0·28 ±0·02 l/kg) and plasma clearance (3·23±0·38 ml/min/kg) were comparable with those in normal healthy volunteers suggesting that the drug handling is not appreciably altered in this group of patients. The administration of 12·5 mg/kg (max 1 g), 6-hourly achieved levels that were up to 3·5 times MICs of most relevant bacteria. The drug therefore has a potential use as empirical monotherapy in febrile neutropenic patients. [ABSTRACT FROM PUBLISHER]
Databáze: Complementary Index